<DOC>
	<DOCNO>NCT00202878</DOCNO>
	<brief_summary>This randomize , active-control , double-blind study subject stabilize high-risk acute coronary syndrome ( ACS ) . The primary objective evaluate clinical benefit Ezetimibe/Simvastatin Combination 10/40 ( single tablet , brand VYTORIN United States ) compare Simvastatin 40 mg. As per original protocol , low-density lipoprotein cholesterol ( LDL-C ) response inadequate , dose simvastatin VYTORIN arm simvastatin arm , could increase 80 mg ( Note : per June 2011 protocol amendment , criterion continue use 80 mg simvastatin modify new increase simvastatin dose 80 mg stop ) . Clinical benefit define reduction risk occurrence composite endpoint cardiovascular ( CV ) death , major coronary event , stroke .</brief_summary>
	<brief_title>IMPROVE-IT : Examining Outcomes Subjects With Acute Coronary Syndrome : Vytorin ( Ezetimibe/Simvastatin ) v Simvastatin ( P04103 )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Clinically stable participant may eligible enroll within 10 day follow hospital admission highrisk acute coronary syndrome ( either STelevation myocardial infarction [ STEMI ] NonSTEMI unstable angina ) Participants take statin must LDLC 125 mg/dl less . Participants take statin must LDLC 100 mg/dl less . Pregnant lactate woman , intend become pregnant Participant active liver disease persistent unexplained serum transaminase elevation History alcohol drug abuse History sensitivity statin ezetimibe A participant discontinuation exist lipid lower regimen pose unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>cholesterol</keyword>
	<keyword>randomize controlled trial</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>angina</keyword>
</DOC>